Case Type: Mergers & Acquisitions

ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed sale to Oruka Therapeutics. Under the terms of the agreement, ABIO shareholders are expected to own approximately 2.38% of the combined company.

ChampionX Corp. (Nasdaq: CHX), relating to its proposed sale to Schlumberger Ltd. Under the terms of the agreement, CHX shareholders are expected to receive 0.735 shares of Schlumberger per share they own.

Nuvei Corp. (Nasdaq: NVEI), relating to its proposed sale to Advent International. Under the terms of the agreement, NVEI shareholders are expected to receive $34.00 in cash per share they own.

Doma Holdings, Inc. (NYSE: DOMA), relating to its proposed sale to Title Resources Group. Under the terms of the agreement, DOMA shareholders are expected to receive $6.29 in cash per share they own.

Capital Bancorp, Inc. (Nasdaq: CBNK), relating to its proposed merger with Integrated Financial Holdings, Inc. Under the terms of the agreement, CBNK shareholders are estimated to receive $5.36 in cash and 1.115 shares of Capital common stock per share they own.

AdTheorent Holding Co. (Nasdaq: ADTH), relating to its proposed sale to Cadent, LLC. Under the terms of the agreement, ADTH shareholders are expected to receive $3.21 in cash per share they own.

Touchstone Bankshares, Inc. (Other OTC: TSBA), relating to its proposed merger with First National Corp. Under the terms of the agreement, TSBA shareholders are expected to receive 0.8122 shares of First National per share they own.

Landos Biopharma, Inc. (NASDAQ: LABP), relating to its proposed sale to AbbVie, Inc. Under the terms of the agreement, LABP shareholders are expected to receive $20.42 in cash plus one non-tradable CVR worth up to $11.14 per share they own.

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, FUSN shareholders are expected to receive $21.00 in cash plus one non-tradable CVR worth up to $3.00 per share they own.

ANSYS, Inc. (Nasdaq: ANSS), relating to its proposed sale to Synopsys, Inc. Under the terms of the agreement, ANSS shareholders are expected to receive approximately 0.345 shares of Synopsys and $197.00 in cash per share they own.